| Trial ID: | L0245 |
| Source ID: | NCT01277497
|
| Associated Drug: |
Sevelamer Carbonate
|
| Title: |
Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Sevelamer carbonate|DRUG: Calcium acetate
|
| Outcome Measures: |
Primary: The primary outcome measure will be the change in FGF-23 concentrations, 12 weeks | Secondary: Change in vascular calcification biomarker levels, 12 weeks|Change in endothelial dysfunction biomarker levels., 12 Weeks|Change in inflammatory biomarker levels, 12 Weeks
|
| Sponsor/Collaborators: |
Sponsor: Albany College of Pharmacy and Health Sciences | Collaborators: Albany Medical College|Genzyme, a Sanofi Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2011-01
|
| Completion Date: |
2016-03
|
| Results First Posted: |
|
| Last Update Posted: |
2016-01-14
|
| Locations: |
Albany Medical Center South Clinical Campus, Albany, New York, 12208, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01277497
|
